Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
CONSHOHOCKEN, PA—Silvana Battaglia, Executive Vice President of Cencora, Inc. (NYSE:COR), recently sold 5,000 shares of the company’s common stock. The shares were sold at a price of $242.24 each, amounting to a total transaction value of $1,211,200. This sale leaves Battaglia with 15,373.889 shares owned directly following the transaction. The stock is currently trading near its 52-week high, with InvestingPro analysis indicating the company is slightly undervalued based on its Fair Value calculations.
Cencora, formerly known as AmerisourceBergen Corp, is a significant player in the wholesale drug industry, with a market capitalization of $47.49 billion. The company has maintained dividend payments for 25 consecutive years and currently offers a dividend yield of 0.91%. According to InvestingPro, which provides comprehensive analysis of 1,400+ US stocks through its Pro Research Reports, Cencora demonstrates good financial health and has delivered strong returns over the past five years.
In other recent news, Cencora Inc. has announced a significant upward revision of its fiscal year 2025 adjusted earnings per share (EPS) guidance following the acquisition of Retina Consultants of America. The acquisition, valued at $4.4 billion, is expected to enhance Cencora’s specialty medical services, raising the EPS outlook to a range of $15.15 to $15.45. Meanwhile, Leerink Partners has increased Cencora’s stock price target to $301, maintaining an Outperform rating after the company’s robust first-quarter results. Mizuho (NYSE:MFG) Securities also initiated coverage with an Outperform rating and a $280 price target, citing confidence in Cencora’s financial goals and strong position in the Specialty/Biopharma Services sector.
Additionally, Cencora disclosed the upcoming retirement of board members Richard W. Gochnauer and Kathleen W. Hyle, set for March 2025. BofA Securities raised its price target for Cencora to $260, reflecting optimism in the company’s innovation capabilities demonstrated at its recent Product Showcase event. The event highlighted advancements in inventory management and clinical trial support, reinforcing Cencora’s commitment to expanding its supply chain solutions. These developments indicate Cencora’s strategic moves to strengthen its market position and enhance shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.